Developmental cognitive delay encompasses intellectual disabilities arising from prenatal, perinatal, or early postnatal injury or genetic factors.
Developmental cognitive delay encompasses intellectual disabilities arising from prenatal, perinatal, or early postnatal injury or genetic factors. Stem cell research in this field concentrates on neurogenic cells—progenitors capable of differentiating into neurons and supporting glial cells—and placental mesenchymal stem cells (MSCs), which secrete neuroprotective factors. The therapeutic rationale rests on replacing damaged neural tissue and reducing neuroinflammation in developing brains. Neurogenic cells, often derived from foetal sources or reprogrammed from adult tissue, may promote rewiring of neural circuits impaired by anoxia, infection, or genetic dysgenesis. Placental MSCs offer an allogeneic, non-invasive source with immunomodulatory properties. Two registered trials and one actively recruiting study are currently investigating safety and functional outcomes in paediatric populations.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Main cell types studied | Neurogenic Cells, MSCs from Amniotic Membrane |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 2 · 1 recruiting now |
For the clinic's own description, see how Stem Plus describes its Developmental Cognitive Delay programme ↗.
Two completed trials and one recruiting study form the current evidence base. Early-phase research focuses on safety in children aged 2–8 years with non-progressive intellectual disability. Published case series report modest improvements in adaptive behaviour and gross motor milestones over 6–12 months post-infusion. Functional MRI in a small cohort suggested increased activation in key learning circuits. No randomised controlled trials have been completed; comparisons are limited to historical natural history data. Effect magnitude remains unclear; blinded, sham-controlled designs are absent, limiting causal inference.
Depending on assessment, a Developmental Cognitive Delay protocol may draw on:
Treatments for developmental delay cost €4,500–7,500 per protocol in specialised neurodevelopmental centres. Neurogenic cell therapies command higher costs (€6,500–8,000) due to manufacturing complexity and regulatory oversight. Placental MSC infusions are moderately priced (€4,500–6,000). Most protocols involve 2–4 infusions over 6–12 months. No paediatric insurance scheme reimburses cell therapy for cognitive delay outside experimental frameworks. Families bear full out-of-pocket expense, creating significant access barriers in lower-income regions.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Developmental Cognitive Delay cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Developmental Cognitive Delay.
Full Developmental Cognitive Delay FAQ → · Developmental Cognitive Delay cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка